Product

Repagermanium

1 clinical trial

1 indication

Indication

Clinical trial

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Status: Terminated, Estimated PCD: 2022-08-15